

EXHIBIT A
MARKED UP VERSION OF CLAIMS CHANGES

4. (Amended) A vector comprising the nucleic acid molecule of [Claims] Claim 1[, 2, or 3].

[6. The host cell of Claim 5 that is a eukaryotic cell.]

[7. The host cell of Claim 5 that is a prokaryotic cell.]

12. (Amended) A process for determining whether a compound inhibits Cloaked-2 polypeptide activity or production comprising exposing a cell according to [Claims] Claim 5[, 6, or 7] to the compound, and measuring Cloaked-2 polypeptide activity or production in said host cell.

22. (Amended) An isolated polypeptide encoded by the nucleic acid molecule of [Claims] Claim 1[, 2, or 3].

25. (Amended) An antibody or fragment thereof that specifically binds the polypeptide of any one of Claims 13, 14, or 15.

28. (Amended) A method of detecting or quantitating the amount of Cloaked-2 polypeptide using the anti-Cloaked-2 antibody or fragment of any one of Claims 24, 25, or 26.

29. (Amended) A selective binding agent or fragment thereof that specifically binds at least one polypeptide wherein said polypeptide comprises the amino acid sequence selected from the group consisting of:

[1.] (a) the amino acid sequence as set forth in SEQ ID NO:2 or SEQ ID NO:4; and

[2.] (b) a fragment of the amino acid sequence set forth in at least one of SEQ ID NO:2 or SEQ ID NO:4; and

[3.] (c) a naturally occurring variant of (a) or (b).

[37. The selective binding agent of Claim 29 that is an antiidiotypic antibody or a fragment thereof.]

45. (Amended) A hybridoma that produces a selective binding agent capable of binding a polypeptide according to any one of Claims [1, 2, or 3] 13, 14, or 15.

46. (Amended) A composition comprising the polypeptide of [Claims] Claim 13[, 14, or 15] and a pharmaceutically acceptable formulation agent.

49. (Amended) A polypeptide comprising a derivative of the polypeptide of [Claims] Claim 13[, 14, or 15].

52. (Amended) A composition comprising a nucleic acid molecule of [Claims] Claim 1[, 2, or 3] and a pharmaceutically acceptable formulation agent.

54. (Amended) A viral vector comprising a nucleic acid molecule of [Claims] Claim 1[, 2, or 3].

55. (Amended) A fusion polypeptide comprising the polypeptide of [Claims] Claim 13[, 14, or 15] fused to a heterologous amino acid sequence.

57. (Amended) A method for treating, preventing or ameliorating a medical condition comprising administering to a patient the polypeptide of [Claims] Claim 13[, 14, or 15] or the polypeptide encoded by the nucleic acid of [Claims] Claim 1[, 2, or 3].

58. (Amended) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of [Claims] Claim 13[, 14, or 15] or the polypeptide encoded by the nucleic acid molecule of [Claims]

Claim 1[, 2, or 3] in a sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

59. (Amended) A device, comprising:

(a) a membrane suitable for implantation; and

(b) cells encapsulated within said membrane, wherein said cells secrete a protein of [Claims] Claim 13[, 14, or 15], and wherein said membrane is permeable to said protein and impermeable to materials detrimental to said cells.

60. A method of identifying a compound which binds to a polypeptide comprising:

(a) contacting the polypeptide of [Claims] Claim 13[, 14, or 15] with a compound;
and

(b) determining the extent of binding of the polypeptide to the compound.

61. A method of modulating levels of a polypeptide in an animal comprising administering to the animal the nucleic acid molecule of [Claims] Claim 1[, 2, or 3].

62. A transgenic non-human mammal comprising the nucleic acid molecule of [Claims] Claim 1[, 2, or 3].

BEST AVAILABLE COPY